https://stock.noler.com/us/stock/akcea-therapeutics-inc https://stock.noler.com/us/stock/akcea-therapeutics-inc/accounts-payable https://stock.noler.com/us/stock/akcea-therapeutics-inc/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/accounts-receivable https://stock.noler.com/us/stock/akcea-therapeutics-inc/accretion-amortization-of-discounts-and-premiums-investments https://stock.noler.com/us/stock/akcea-therapeutics-inc/accrued-liabilities-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/accumulated-depreciation https://stock.noler.com/us/stock/akcea-therapeutics-inc/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/akcea-therapeutics-inc/adjustment-to-additional-paid-in-capital-income-tax-effect-from-share-based-compensation-net https://stock.noler.com/us/stock/akcea-therapeutics-inc/adjustments-related-to-tax-withholding-for-share-based-compensation https://stock.noler.com/us/stock/akcea-therapeutics-inc/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/allowance-for-doubtful-accounts-receivable https://stock.noler.com/us/stock/akcea-therapeutics-inc/amortization https://stock.noler.com/us/stock/akcea-therapeutics-inc/aoci https://stock.noler.com/us/stock/akcea-therapeutics-inc/area-of-real-estate-property https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-debt-accumulated-gross-unrealized-gain-before-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-debt-accumulated-gross-unrealized-loss-before-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-debt-amortized-cost-basis https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-debt-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-debt-securities https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-in-unrealized-loss-positions-qualitative-disclosure-number-of-positions https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-12-months-or-longer-loss https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-fair-value https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-less-than-12-months-loss https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-less-than-twelve-months-fair-value https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-loss https://stock.noler.com/us/stock/akcea-therapeutics-inc/available-for-sale-unrealized-loss-position-twelve-months-or-longer-fair-value https://stock.noler.com/us/stock/akcea-therapeutics-inc/basic-shares https://stock.noler.com/us/stock/akcea-therapeutics-inc/capital-expenditures https://stock.noler.com/us/stock/akcea-therapeutics-inc/capital-expenditures-incurred-but-not-yet-paid https://stock.noler.com/us/stock/akcea-therapeutics-inc/cash-and-cash-equivalents-change https://stock.noler.com/us/stock/akcea-therapeutics-inc/cash-and-equivalents https://stock.noler.com/us/stock/akcea-therapeutics-inc/cash-and-restricted-cash https://stock.noler.com/us/stock/akcea-therapeutics-inc/cash-cash-equivalents-and-short-term-investments https://stock.noler.com/us/stock/akcea-therapeutics-inc/cash-flow-breakdown https://stock.noler.com/us/stock/akcea-therapeutics-inc/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/akcea-therapeutics-inc/common-stock-value https://stock.noler.com/us/stock/akcea-therapeutics-inc/comprehensive-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/akcea-therapeutics-inc/contract-liability https://stock.noler.com/us/stock/akcea-therapeutics-inc/contract-with-customer-asset-net-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/contract-with-customer-liability-noncurrent https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-after-fifth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-fifth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-fourth-and-fifth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-fourth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-second-and-third-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-second-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-due-in-third-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/contractual-obligation-future-minimum-payments-due-remainder-of-fiscal-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/akcea-therapeutics-inc/conversion-of-stock-shares-issued https://stock.noler.com/us/stock/akcea-therapeutics-inc/cost-of-goods-and-services-sold-amortization https://stock.noler.com/us/stock/akcea-therapeutics-inc/costs-and-expenses https://stock.noler.com/us/stock/akcea-therapeutics-inc/cover-page-shares-outstanding https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-foreign-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-income-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/current-state-and-local-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/debt-conversion-converted-instrument-shares-issued https://stock.noler.com/us/stock/akcea-therapeutics-inc/debt-conversion-original-debt-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-federal-income-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-foreign-income-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-income-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-income-tax-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-rent-credit-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-rent-credit-noncurrent https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-revenue https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-revenue-noncurrent https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-revenue-recognized https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-state-and-local-income-tax-expense-benefit https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-deferred-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-goodwill-and-intangible-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-gross https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-liabilities-net https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-other https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-stock-compensation https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-tax-credit-carryforwards https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-liabilities-goodwill-and-intangible-assets-intangible-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/deferred-tax-liabilities-other https://stock.noler.com/us/stock/akcea-therapeutics-inc/defined-contribution-plan-cost-recognized https://stock.noler.com/us/stock/akcea-therapeutics-inc/depreciation https://stock.noler.com/us/stock/akcea-therapeutics-inc/diluted-shares https://stock.noler.com/us/stock/akcea-therapeutics-inc/dilutive-shares https://stock.noler.com/us/stock/akcea-therapeutics-inc/due-from-related-parties-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/due-to-related-parties-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/akcea-therapeutics-inc/effective-tax-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/employee-related-liabilities-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/akcea-therapeutics-inc/fair-value-assets-level-1-to-level-2-transfers-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/fair-value-assets-level-2-to-level-1-transfers-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/financing-cash-flow https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-after-year-five https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-next-twelve-months https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-remainder-of-fiscal-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-five https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-four https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-three https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-amortization-expense-year-two https://stock.noler.com/us/stock/akcea-therapeutics-inc/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/akcea-therapeutics-inc/foreign-pretax-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/form-d-stocks https://stock.noler.com/us/stock/akcea-therapeutics-inc/general-and-administrative-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/impairment-of-intangible-assets-finitelived https://stock.noler.com/us/stock/akcea-therapeutics-inc/income-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-accrued-income-taxes-payable https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-contract-with-customer-asset https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-contract-with-customer-liability https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-deferred-revenue https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-due-to-related-parties-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-income-taxes-receivable https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-inventories https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-other-employee-related-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/increase-decrease-in-other-operating-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/insider-transactions-other https://stock.noler.com/us/stock/akcea-therapeutics-inc/insider-transactions-preferred https://stock.noler.com/us/stock/akcea-therapeutics-inc/insider-transactions-stock-options https://stock.noler.com/us/stock/akcea-therapeutics-inc/interest-expense-related-party https://stock.noler.com/us/stock/akcea-therapeutics-inc/inventory https://stock.noler.com/us/stock/akcea-therapeutics-inc/inventory-finished-goods https://stock.noler.com/us/stock/akcea-therapeutics-inc/inventory-raw-materials https://stock.noler.com/us/stock/akcea-therapeutics-inc/inventory-work-in-process https://stock.noler.com/us/stock/akcea-therapeutics-inc/inventory-write-down https://stock.noler.com/us/stock/akcea-therapeutics-inc/investing-cash-flow https://stock.noler.com/us/stock/akcea-therapeutics-inc/investment-income-net https://stock.noler.com/us/stock/akcea-therapeutics-inc/lessee-operating-lease-liability-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/lessee-operating-lease-liability-undiscounted-excess-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/minority-interest-ownership-percentage-by-parent https://stock.noler.com/us/stock/akcea-therapeutics-inc/net-change-in-cash https://stock.noler.com/us/stock/akcea-therapeutics-inc/net-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/net-income-loss-available-to-common-stockholders-basic https://stock.noler.com/us/stock/akcea-therapeutics-inc/noncash-or-part-noncash-acquisition-fixed-assets-acquired https://stock.noler.com/us/stock/akcea-therapeutics-inc/noncash-or-part-noncash-acquisition-intangible-assets-acquired https://stock.noler.com/us/stock/akcea-therapeutics-inc/oci-available-for-sale-adjustment-net-of-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/oci-foreign-currency-transaction-and-translation-gain-loss-arising-net-of-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/oci-net-of-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/oci-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/oci-unrealized-holding-gain-loss-on-securities-arising-net-of-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-cash-flow https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-expenses https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-cost https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-lease-income-lease-payments https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-liability https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-liability-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-liability-noncurrent https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-2 https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-after-year-five https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-current https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-in-four-and-five-years https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-in-two-and-three-years https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-next-twelve-months https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-thereafter https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-year-five https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-year-four https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-year-three https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-payments-due-year-two https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-right-of-use-asset-amortization-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/operating-lease-weighted-average-discount-rate-percent https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-current-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-current-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-noncurrent-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-noncurrent-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-nonoperating-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/other-nonoperating-income-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/akcea-therapeutics-inc/paid-in-capital-tax-effect-from-share-based-compensation https://stock.noler.com/us/stock/akcea-therapeutics-inc/payments-for-restructuring https://stock.noler.com/us/stock/akcea-therapeutics-inc/payments-of-stock-issuance-costs https://stock.noler.com/us/stock/akcea-therapeutics-inc/payments-to-acquire-available-for-sale-debt https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-shares-facts https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-stock-dividends-income-statement-impact https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-stock-shares-authorized https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/akcea-therapeutics-inc/preferred-stock-value https://stock.noler.com/us/stock/akcea-therapeutics-inc/pretax-income https://stock.noler.com/us/stock/akcea-therapeutics-inc/pretax-income-domestic https://stock.noler.com/us/stock/akcea-therapeutics-inc/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-contributions-from-parent https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-issuance-initial-public-offering https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-issuance-of-convertible-preferred-stock https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-issuance-of-private-placement https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-issuance-of-shares-under-incentive-and-share-based-compensation-plans-including-stock-options https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-issuance-or-sale-of-equity https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-repayments-of-related-party-debt https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-sale-and-maturity-of-available-for-sale-securities https://stock.noler.com/us/stock/akcea-therapeutics-inc/proceeds-from-stock-issued https://stock.noler.com/us/stock/akcea-therapeutics-inc/profit-loss https://stock.noler.com/us/stock/akcea-therapeutics-inc/property-plant-and-equipment-gross https://stock.noler.com/us/stock/akcea-therapeutics-inc/property-plant-equipment https://stock.noler.com/us/stock/akcea-therapeutics-inc/public-float https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-due-after-fifth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-due-in-fourth-and-fifth-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-due-in-next-twelve-months https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-due-in-second-and-third-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-due-in-second-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/purchase-obligation-future-minimum-payments-remainder-of-fiscal-year https://stock.noler.com/us/stock/akcea-therapeutics-inc/receivables-long-term-contracts-or-programs https://stock.noler.com/us/stock/akcea-therapeutics-inc/research-and-development-expense-excluding-acquired-in-process-cost https://stock.noler.com/us/stock/akcea-therapeutics-inc/restricted-cash https://stock.noler.com/us/stock/akcea-therapeutics-inc/restructuring-charges https://stock.noler.com/us/stock/akcea-therapeutics-inc/restructuring-costs https://stock.noler.com/us/stock/akcea-therapeutics-inc/restructuring-reserve https://stock.noler.com/us/stock/akcea-therapeutics-inc/restructuring-reserve-accrual-adjustment https://stock.noler.com/us/stock/akcea-therapeutics-inc/retained-earnings https://stock.noler.com/us/stock/akcea-therapeutics-inc/revenue https://stock.noler.com/us/stock/akcea-therapeutics-inc/revenue-from-contract-with-customer-excluding-assessed-tax https://stock.noler.com/us/stock/akcea-therapeutics-inc/right-of-use-asset-obtained-in-exchange-for-operating-lease-liability https://stock.noler.com/us/stock/akcea-therapeutics-inc/sale-of-stock-consideration-received-on-transaction https://stock.noler.com/us/stock/akcea-therapeutics-inc/severance-costs https://stock.noler.com/us/stock/akcea-therapeutics-inc/sga-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/shareholders-equity https://stock.noler.com/us/stock/akcea-therapeutics-inc/shares-authorized https://stock.noler.com/us/stock/akcea-therapeutics-inc/shares-issued https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-based-compensation https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-compensation-unrecognized-cost-stock-options https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-issued-new-shares-sold https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-issued-shares-issued-value-restricted-stock-award-net-of-forfeitures https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-issued-shares-issued-value-share-based-compensation-gross https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-issued-shares-issued-value-stock-options-exercised https://stock.noler.com/us/stock/akcea-therapeutics-inc/stock-split-ratio https://stock.noler.com/us/stock/akcea-therapeutics-inc/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-tax-credits https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-rate-reconciliation-tax-cuts-and-jobs-act-transition-tax-on-accumulated-foreign-earnings-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-change-in-enacted-tax-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-foreign-income-tax-rate-differential https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-nondeductible-expense-share-based-compensation-cost https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-reconciliation-tax-credits https://stock.noler.com/us/stock/akcea-therapeutics-inc/tax-withholding-on-stock-awards https://stock.noler.com/us/stock/akcea-therapeutics-inc/total-assets https://stock.noler.com/us/stock/akcea-therapeutics-inc/total-liabilities https://stock.noler.com/us/stock/akcea-therapeutics-inc/total-liabilities-and-equity https://stock.noler.com/us/stock/akcea-therapeutics-inc/unrecognized-tax-benefits https://stock.noler.com/us/stock/akcea-therapeutics-inc/utb-decrease-from-prior-year-positions https://stock.noler.com/us/stock/akcea-therapeutics-inc/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/akcea-therapeutics-inc/utb-increase-from-current-year-positions https://stock.noler.com/us/stock/akcea-therapeutics-inc/utb-increase-from-prior-year-positions https://stock.noler.com/us/stock/akcea-therapeutics-inc/utb-that-would-impact-effective-tax-rate https://stock.noler.com/us/stock/akcea-therapeutics-inc/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/akcea-therapeutics-inc/weighted-average-number-of-share-outstanding-basic-and-diluted